Prolia (Denosumab) Cost in Massachusetts: Prices, Insurance, and Savings in 2026

What Prolia (Denosumab) Costs at Massachusetts Pharmacies Without Insurance

The manufacturer list price set by Amgen for a single 60 mg prefilled syringe of Prolia is approximately $1,500. That figure translates directly to the average 2026 cash-pay price at Massachusetts retail pharmacies, because denosumab is a branded biologic without a generic equivalent currently on the market. The injection is given once every six months in a healthcare setting, so an uninsured patient paying full price would spend roughly $3,000 per year.

Prices can shift by a few percentage points depending on the pharmacy. Hospital outpatient infusion centers in the Boston metro area sometimes bill a facility fee on top of the drug cost, pushing total charges above $1,800 per administration. Specialty pharmacies affiliated with academic medical centers like Mass General Brigham or Beth Israel Deaconess may negotiate marginally different acquisition costs, but the sticker price to uninsured patients stays close to the Amgen list. The FDA-approved prescribing information for Prolia specifies a flat 60 mg dose regardless of body weight, which means there is no dose-based variability to exploit for savings [1].

For patients without insurance, that $3,000 annual cost often becomes the deciding factor between starting denosumab and choosing an oral bisphosphonate like alendronate, which can cost under $15 per month at many Massachusetts pharmacies.

MassHealth (Massachusetts Medicaid) Coverage for Prolia

MassHealth covers Prolia with prior authorization. The approval pathway typically requires documentation that the patient has a qualifying diagnosis (postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, or bone loss related to hormone ablation therapy for cancer) and, in many cases, evidence of intolerance to or failure of an oral bisphosphonate.

The prior authorization process through MassHealth usually takes 5 to 10 business days. Prescribers submit a PA request through the MassHealth Drug Utilization Review Program, and the state reviews against its preferred drug list criteria. Once approved, the patient's cost share depends on their specific MassHealth plan tier, but most enrollees pay $0 to $3.65 per prescription under current MassHealth copay structures.

One detail that catches patients off guard: Prolia is classified as a medical benefit (not a pharmacy benefit) by many payers when it is administered in a provider's office. MassHealth can process it under either pathway, but if billed as a medical benefit under Part B-equivalent coverage, the PA requirements and cost-sharing rules may differ. Patients should confirm with their MassHealth managed care organization (such as BMC HealthNet or Tufts Health Together) which benefit pathway applies to their plan.

The clinical rationale supporting MassHealth's coverage decision aligns with the FREEDOM trial (N=7,868), which demonstrated that denosumab 60 mg every six months reduced the incidence of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo [2]. The Endocrine Society's 2020 clinical practice guideline lists denosumab as a first-line option for postmenopausal women at high fracture risk [3].

How Commercial Insurance Plans in Massachusetts Handle Prolia

Most commercial insurers operating in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care (now Point32Health), Tufts Health Plan, and Fallon Health, cover Prolia. Coverage almost always requires prior authorization and frequently involves step therapy, meaning the insurer wants to see that the patient tried and failed (or cannot tolerate) a first-line oral bisphosphonate before approving denosumab.

Typical commercial plan cost-sharing for Prolia falls into one of three buckets. Plans with a specialty drug tier may assign a coinsurance of 20% to 30%, which on a $1,500 drug means $300 to $450 per injection out of pocket before any manufacturer assistance. Plans that classify it under a standard injectable tier may set a flat copay between $50 and $150. And high-deductible health plans paired with an HSA may require the patient to cover the full $1,500 until the deductible is met.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a principal investigator on the FREEDOM trial, has noted: "The cost barrier for denosumab is real, but for patients who cannot take oral bisphosphonates, it remains one of the most effective antiresorptive therapies available, and most insurers recognize that."

Patients on employer-sponsored plans governed by ERISA (a federal law) may face different formulary rules than those on state-regulated small-group or individual plans. Massachusetts state-regulated plans must comply with the Division of Insurance essential health benefit benchmark, which includes coverage for osteoporosis treatment, but the specific formulary placement of Prolia is at the insurer's discretion.

The Amgen Prolia Savings Card: How It Works in Massachusetts

Amgen offers a copay assistance program through the Prolia savings card that can reduce out-of-pocket costs to $0 for eligible commercially insured patients. The program covers up to $1,500 in copay or coinsurance costs per injection, effectively zeroing out the patient's share for most commercial plans.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Prolia, must not be enrolled in any federal or state government healthcare program (including Medicare, Medicaid, TRICARE, or VA benefits), and must be a resident of the United States. Massachusetts residents on MassHealth or Medicare Part B are not eligible.

To enroll, patients call the number on the Amgen website or ask their prescriber's office to register them. The card is applied at the point of sale or billing. If Prolia is administered in a physician's office and billed under the medical benefit, the savings card can still be applied, but the office staff must submit a separate claim to Amgen's processor. This step is sometimes missed, resulting in the patient receiving a surprise bill. Patients should proactively ask the billing department to apply the card before the injection appointment.

One limitation: the savings card has an annual maximum. Amgen adjusts this ceiling periodically, so patients should verify the current cap at enrollment. As of early 2026, the program covers up to $3,000 per year (two injections), which aligns with the expected out-of-pocket cost for most commercially insured patients.

Compounded Denosumab in Massachusetts: Legal Status and Availability

Compounded denosumab is available in Massachusetts through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions, provided they meet specific conditions: the compounded product must be prescribed for an identified patient, the pharmacy cannot advertise the compounded drug, and the preparation must comply with United States Pharmacopeia (USP) standards.

Massachusetts regulates compounding pharmacies through the Board of Registration in Pharmacy, which enforces compliance with USP <797> (sterile compounding) and USP <800> (hazardous drugs) standards. A 503A pharmacy in Massachusetts can legally compound denosumab if a licensed prescriber writes a patient-specific prescription and the pharmacy holds the appropriate sterile compounding license.

The cost picture for compounded denosumab differs significantly from the branded product. Some 503A pharmacies offer compounded versions at substantially reduced prices compared to the $1,500 Amgen list price. Patients should be aware of several caveats. Compounded biologics are not FDA-approved, are not AB-rated as therapeutically equivalent to Prolia, and are not subject to the same manufacturing oversight as Amgen's product. The FDA has issued guidance clarifying the boundaries between legitimate compounding and manufacturing, and patients should confirm their pharmacy operates within 503A (not 503B outsourcing facility) parameters unless the pharmacy holds 503B registration [4].

A patient considering compounded denosumab should discuss the decision with their prescriber. The American Association of Clinical Endocrinology (AACE) has not issued a formal position on compounded denosumab specifically, but AACE guidelines emphasize using FDA-approved therapies as first-line treatment for osteoporosis whenever possible [5].

Medicare Coverage for Prolia in Massachusetts

Medicare Part B covers Prolia when it is administered by a healthcare provider in an office or outpatient setting, which is the standard route of administration. The patient is responsible for the Part B deductible ($257 in 2026) and then 20% coinsurance on the Medicare-approved amount. For a $1,500 injection, that 20% coinsurance equals approximately $300 per dose after the deductible is met.

Medigap (Medicare Supplement) plans can cover some or all of that 20% coinsurance. Massachusetts is one of the few states that standardizes Medigap plan availability through its own regulatory framework rather than following the federal lettered-plan system exactly. Massachusetts Medigap plans (Core, Supplement 1, and Supplement 1A) vary in their coverage of Part B coinsurance, so patients should check their specific plan documents.

Medicare Advantage plans (Part C) operating in Massachusetts, such as those offered by Tufts Health Plan Medicare Preferred, Blue Cross Medicare Advantage, or Aetna Medicare, set their own prior authorization and cost-sharing rules. Most cover Prolia, but the PA requirements and copay or coinsurance amounts differ by plan. The Centers for Medicare & Medicaid Services requires that Medicare Advantage plans cover everything Original Medicare covers, but they can impose utilization management tools like PA [6].

One critical note for Medicare patients: the Amgen savings card cannot be used with Medicare. Applying manufacturer copay assistance to a federally funded program violates the Anti-Kickback Statute. Medicare patients seeking financial help should instead contact the Amgen Safety Net Foundation, which provides Prolia at no cost to patients who meet income-based eligibility criteria.

Telehealth Prescribing of Prolia in Massachusetts

Massachusetts permits telehealth prescribing of Prolia. A provider licensed in Massachusetts can evaluate a patient via video visit, review bone density results and fracture history, and write a prescription for denosumab. The actual injection, however, must be performed in person, either at the prescriber's office, a participating infusion center, or a home health visit.

The Massachusetts Board of Registration in Medicine updated its telehealth policies during the COVID-19 public health emergency, and the state legislature made many of those flexibilities permanent through Chapter 260 of the Acts of 2020. Prescribers do not need a separate telehealth license to practice in Massachusetts, provided they hold an active Massachusetts medical license.

This hybrid model (telehealth consultation plus in-person injection) works well for patients in western Massachusetts or Cape Cod who may live far from a specialist. A patient in Springfield, for example, could consult with an endocrinologist at a Boston academic center via telehealth, receive a Prolia prescription, and then have the injection administered at a local clinic.

According to data published in the Journal of Bone and Mineral Research, adherence to denosumab's every-six-month dosing schedule is clinically important because discontinuation leads to a rapid rise in bone turnover markers within 6 to 12 months and potential rebound vertebral fractures [7]. The Bone et al. 2011 analysis of FREEDOM extension data confirmed that continuous treatment over 6 years provided sustained fracture risk reduction and progressive BMD gains at the lumbar spine (13.7%) and total hip (7.0%) [8]. Telehealth-based monitoring can help keep patients on schedule by reducing the friction of follow-up appointments.

Other Discount Programs and Patient Assistance Options

Beyond the Amgen savings card, several pathways exist for reducing Prolia costs in Massachusetts. The Amgen Safety Net Foundation provides Prolia free of charge to uninsured or underinsured patients who meet household income requirements (generally at or below 400% of the federal poverty level). Applications require documentation of income and insurance status.

NeedyMeds and RxAssist maintain updated databases of patient assistance programs, and both list the Amgen program. Some Massachusetts hospitals, particularly community health centers, participate in the 340B Drug Pricing Program, which allows qualifying facilities to purchase drugs at a significant discount. Patients receiving care at a 340B-eligible site may benefit from lower out-of-pocket costs, although the savings are not always passed through to the patient directly.

Pharmacy benefit manager (PBM) discount cards from GoodRx, SingleCare, and similar platforms occasionally list Prolia, but the discounts on specialty biologics are minimal compared to their impact on generic medications. A GoodRx coupon might reduce a $1,500 Prolia injection to $1,350 at select pharmacies, which is helpful but not significant.

For patients who qualify, the Health Safety Net program in Massachusetts provides coverage for certain medical services for residents with incomes up to 300% of the federal poverty level who are not eligible for MassHealth. This program could potentially cover Prolia when administered in an acute care hospital setting.